Although these studies suggested that blocking IL-17RA in asthma might be promising, studies with the anti-IL-17RA monoclonal antibody brodalumab have failed to show benefit in asthma119, implying that blocking IL-25 alone is insufficient to modify disease. Here, IL17RA is linked to asthma.